Skip to NavigationSkip to content

Sanofi's Jevtana doubles progression-free survival in metastatic castration-resistant prostate cancer

Published on 01/10/19 at 11:32am

Sanofi was present at the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona this year to reveal new data showing that its microtubule inhibitor Jevtana (cabazitaxel) met its primary endpoint in the treatment of metastatic castration-resistant prostate cancer (mCRPC) when combined with prednisone.

It was shown that the combo more than doubled radiographic progression free survival (rPFS) to a median of eight months, compared to 3.7 months with abiraterone or enzalutamide, clearing the primary endpoint of the study.

Jevtana also extended overall survival by a median of 13.6 months compared to 11 months and reduced any-cause risk of death by 36% compared to abiraterone or enzalutamide, meeting a key secondary endpoint of the trial. Progression-free survival was also improved by a median 4.4 months versus 2.7.

The findings related specifically to 255 mCRPC patients with a median age of 70 years who were previously treated with docetaxel and who progressed within 12 months on an androgen receptor (AR)-targeted agent

“In this study, treatment with Jevtana significantly improved radiographic progression free survival and overall survival compared with enzalutamide or abiraterone,” said Professor Ronald de Wit from Erasmus MC University Hospital, Rotterdam, and the lead investigator of the CARD study. “These results are exciting as they have the potential to impact treatment guidelines for metastatic prostate cancer and current clinical practice.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches